Keywords: merck, cordaptive, positive, impact, key, lipid, parameters

Merck's Cordaptive has positive impact on key lipid parameters

Article | 10 September 2007

Print This

US drugmaker Merck & Co says that results from a Phase III trial of Cordaptive (extended-release niacin/laropiprant) show that the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in